02367 GIANT BIOGENE
- 52.000
- +1.750+3.48%
GIANT BIOGENE News
Giant Biotech (02367.HK): Kefumei's large single product volume continues to focus on medical and aesthetic products approved for catalysis
Giant Life (02367.HK): Good Wind takes the lead in recombinant collagen to Qingyun
Giant Biotech (2367.HK) Investment Value Analysis Report: The recombinant collagen market is expected to grow rapidly, and the company's star products achieve word-of-mouth and sales growth
Giusi Biotech (02367.HK) Annual Report Review Report: The company's performance achieved impressive growth and steadily promoted the collaborative development of cosmetic equipment
Giant Biotech (2367.HK) 2023 Report Review: Expanding Multiple Categories and Multiple Scenes to Accelerate Online Penetration
Giusi Biotech (2367.HK) 2023 Annual Report Review: Performance Exceeds Expectations, Skin Revitalization Products are progressing smoothly
Giant Biotech (02367.HK): The core single product, a high-speed growth injection product, is about to be launched
Giant Biotech (02367.HK): Big Single Product Methodology Begins to Show Optimism for Collaborative Development of Makeup Devices
Giant Biotech (2367.HK): Annual results exceeded expectations and expected progress in injectable products
Giuzi Biotech (2367.HK) 2023 Annual Report Review: Strong revenue performance in '23, star products have strong potential, and the professional skincare business has performed well
Giant Biotech (02367.HK): Performance exceeded expectations, expected core single product kinetic energy continuation & injection approval settled to open the second curve
Giant Biology (2367.HK): 23 years of excellent results, and 24 years of kinetic energy is expected to continue
Giant Biotech (2367.HK): Performance exceeds expectations and continues to strengthen online channels
Giant Biotech (2367.HK) 2023 Annual Report Review: Kefu Mei's Star Single Product Is Growing Strong, Optimistic About the Development Prospects of Collagen's “Medical and Aesthetic Grade” Business
Giant Biotech (02367.HK) 2023 Annual Report Review: Global Leader in Recombinant Collagen Continues to Release Core Single Products
Giant Biotech (2367.HK): Brand and channel adjustments drive rapid growth in 2024
Giant Biotech (02367.HK): Core products drive high growth, 23-year performance slightly exceeded expectations
Giant Biotech (02367.HK): High performance confirms the superiority of core technology 24 Collagen
Giant Biotech (02367.HK): 23-year performance exceeded expectations, waiting for the release of new cosmetics products+medical and aesthetic approval
Giant Biotech (2367.HK): Performance exceeds expectations, star single product sales help
Analysis
Price Target
No Data
